Related Experiment Video
Updated: Sep 27, 2025
07:44
Evaluation of Synapse Density in Hippocampal Rodent Brain Slices
Published on: October 6, 2017
17.5K
Imaging Synaptic Density: The Next Holy Grail of Neuroscience?
Maria Elisa Serrano1,2, Eugene Kim1,2, Marija M Petrinovic3,4
1Department of Neuroimaging, The BRAIN Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.
Frontiers in Neuroscience
|April 11, 2022
Summary
Quantifying brain synaptic density is crucial for understanding neurological disorders. New in vivo methods like PET tracers offer promise but require further validation for clinical use in diagnosing brain conditions.
Area of Science:
- Neuroscience
- Biomarker Discovery
- Medical Imaging
Background:
- Synapses are vital for brain function, and their dysregulation is linked to neurological and psychiatric disorders.
- Accurate measurement of synaptic density is essential for diagnosing and understanding brain development and disease.
- Current ex vivo methods for assessing synapses are invasive and not suitable for living patients.
Purpose of the Study:
- To review and discuss current ex vivo and in vivo methods for quantifying brain synaptic density.
- To evaluate the reliability and utility of existing and emerging synaptic density measurement techniques.
- To identify challenges hindering the clinical application of synaptic biomarkers for neurological disorders.
Main Methods:
- Review of existing literature on synaptic density quantification methods.
- Analysis of ex vivo techniques such as electron microscopy and immunohistochemistry.
- Evaluation of in vivo approaches including Positron Emission Tomography (PET) tracers and Magnetic Resonance (MR)-based methods.
Main Results:
- Ex vivo methods provide detailed synaptic visualization but are invasive.
- In vivo PET tracers targeting SV2A offer non-invasive assessment of synaptic density.
- Non-invasive MR methods show potential for inferring synaptic information via glutamate neurotransmission.
Conclusions:
- Emerging in vivo methods, particularly PET tracers, represent a paradigm shift for detecting synaptic alterations in patients.
- Both PET and MR methods have advantages and limitations that need to be addressed for clinical integration.
- Overcoming current challenges is critical for utilizing synaptic density biomarkers as diagnostic and prognostic tools in neurological and psychiatric disorders.
